Dr. Reddys Labs (NYSE: RDY) reported Q3 EPS of $0.02, versus ($0.47) reported last year. Revenue for the quarter came in at $675 million, versus $600 million reported last year.

Commenting on the results, Co-chairman & MD, G V Prasad said, “We continued with our growth momentum while maintaining EBITDA margins. The profits were impacted due to trigger based impairment charge taken on a few acquired products including Nuvaring. We are progressing well on the phase 3 clinical trials for Sputnik V vaccine in India. We continue to focus on enhancing our product offerings to our patients to serve them better.”

For earnings history and earnings-related data on Dr. Reddys Labs (RDY) click here.